Evidence map›Paper›PMID 35239141›Full record

ArticleMetabolic brain disease2022

Protective effect of curcumin against rotenone-induced substantia nigra pars compacta neuronal dysfunction.

L V Darbinyan, K V Simonyan, L E Hambardzumyan, L P Manukyan, S H Badalyan, V H Sarkisian

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

L V DarbinyanSensorimotor Integration Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia.
K V SimonyanNeuroendocrine Relationships Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia. karensimonyan1986@yahoo.com.
L E HambardzumyanSensorimotor Integration Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia.
L P ManukyanSensorimotor Integration Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia.
S H BadalyanSensorimotor Integration Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia.
V H SarkisianSensorimotor Integration Laboratory, Orbeli Institute of Physiology NAS RA, 0028, Yerevan, Armenia.
L. A. Orbeli Institute of Physiology NAS RA · AM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rotenone is involved in the degeneration of dopaminergic neurons, and curcumin may prevent or effectively slow the progression of Parkinson's disease (PD). Previous research has shown that the naturally occurring phenolic compound curcumin can reduce inflammation and oxidation, making it a potential therapeutic agent for neurodegenerative diseases. The present study involves investigation of rotenone-induced histological changes in the brain area, hippocampus using Nissl staining after 35 day of subcutaneous injection of rotenone in adult male rats. We sought to determine whether curcumin could protect against rotenone-induced dopaminergic neurotoxicity in a rat model by in vivo electrical recording from Substantia nigra pars compacta (SNc). Curcumin treatment significantly improved electrical activity of neurons in the SNc of rotenone-induced PD model rats. The pattern of histological alterations corresponds with electrophysiological manifestations.

Indexed as

CurcuminParkinson DiseaseAnimalsDopaminergic NeuronsMalePars CompactaRatsRotenoneSubstantia NigraCurcuminRotenoneCurcuminIn vivo electrophysiologyRotenoneSubstantia nigra pars compacta

Identifiers

PMID35239141
OpenAlexW4221064579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.